2.2092
전일 마감가:
$2.24
열려 있는:
$2.23
하루 거래량:
726.50K
Relative Volume:
0.23
시가총액:
$58.49M
수익:
$155.00K
순이익/손실:
$-30.01M
주가수익비율:
-1.3229
EPS:
-1.67
순현금흐름:
$-11.98M
1주 성능:
-7.29%
1개월 성능:
-17.90%
6개월 성능:
-71.47%
1년 성능:
-68.44%
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
INMB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
INMB
Inmune Bio Inc
|
2.20 | 67.26M | 155.00K | -30.01M | -11.98M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
387.80 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.37 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
450.22 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
704.47 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
307.35 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
2025-07-01 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Underperform |
2025-01-28 | 개시 | Rodman & Renshaw | Buy |
2024-10-21 | 개시 | Alliance Global Partners | Buy |
2024-09-27 | 개시 | Raymond James | Outperform |
2024-08-22 | 개시 | Scotiabank | Sector Outperform |
2023-06-01 | 개시 | Robert W. Baird | Outperform |
2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2021-07-07 | 재확인 | Maxim Group | Buy |
2021-04-21 | 개시 | B. Riley Securities | Buy |
2021-01-22 | 재확인 | Maxim Group | Buy |
2020-09-01 | 개시 | BTIG Research | Buy |
2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes - ADVFN Brasil
Intraday Charts Show Spike in INmune Bio Inc. ActivityJuly 2025 Setups & Free Safe Capital Growth Stock Tips - beatles.ru
Can Traders Expect Breakout From INmune Bio Inc. This WeekWeekly Trading Summary & AI Powered Buy/Sell Recommendations - 선데이타임즈
Inmune Bio Inc. shares fall 1.24% premarket after Climb Bio reports financial results and Generation Bio announces new data. - AInvest
INmune Bio Inc. Recovery Potential Based on Technical ToolsChart-Based Trade Entries Gain Analyst Support - beatles.ru
Undervalued Innovators in Biotech: Assessing Altimmune and INmune Bio's High-Risk, High-Reward Potential - AInvest
Inmune Bio’s Earnings Call: Progress Amid Challenges - TipRanks
Inmune Bio Inc. shares fall 2.71% intraday as Climb Bio reports financial results and trial updates. - AInvest
Inmune Bio: Strategic Position and Growth Potential Amid Leadership Change and Promising Pipeline - TipRanks
INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript - Insider Monkey
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift - MSN
Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
INmune Bio CEO Change and Strategic Shift: Core Therapeutic Areas Focus with Potential 199% Price Upside - AInvest
INmune Bio Sets Mid-2026 Timeline for BLA and MAA Filings Amid CEO Transition - AInvest
Earnings call transcript: INmune Bio Q2 2025 reveals wider losses, stock tumbles - Investing.com Nigeria
Earnings call transcript: INmune Bio Q2 2025 reveals wider losses, stock tumbles By Investing.com - Investing.com South Africa
Inmune Bio Inc. shares fall 14.69% premarket after missing primary cognitive endpoints in MINDFuL phase 2 trial. - AInvest
INmune Bio August 2025 slides: three-platform strategy shows clinical progress - Investing.com Nigeria
Why Did INmune Bio Plunge 17.56%? Q2 Loss Widens 110% - AInvest
Transcript : INmune Bio, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
INmune Bio Reports Q2 2025 Net Loss of $24.5 Million, Announces CEO Retirement and $19 Million Registered Direct Offering - AInvest
INmune Bio (INMB) Q2 Loss Widens 110% - AOL.com
INmune Bio Inc (INMB) Q2 2025 Earnings Call Highlights: Promisin - GuruFocus
INmune Bio Reports Q2 2025 Results and Strategic Updates - TipRanks
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
INmune Bio Q2 Loss Worsens Amid Alzheimer's Trial Disappointment, Cash Reserves Increase - AInvest
INmune Bio Completes Phase I/II Trial for INKmune™ - TipRanks
INmune Bio Inc Reports Q2 EPS of -$0.45, Missing Estimates; Reve - GuruFocus
INmune Bio: Navigating the Crossroads of Clinical Promise and Financial Realities - AInvest
INmune Bio reports Q2 financial results, misses primary endpoints in MINDFuL trial - Investing.com Nigeria
INmune Bio reports Q2 financial results, misses primary endpoints in MINDFuL trial By Investing.com - Investing.com South Africa
INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire
INmune Bio Announces Q2 2025 Results, Business Update, and Management Changes - AInvest
INmune Bio's INKmune Hits End Points in mCR Prostate Cancer Trial - CGTLive®
Inmune Bio Inc. shares fall 1.09% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest
Inmune Bio Q2 Earnings Preview: Consensus EPS Estimate at -$0.38 - AInvest
INmune Bio Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Inmune Bio shares fall 4.73% premarket despite positive trial results for INKmune™ in prostate cancer. - AInvest
INmune Bio stock holds steady as Raymond James reiterates Market Perform - Investing.com
INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals - MSN
INmune Bio’s Promising Phase 2 MINDFuL Trial Results Set to Stir Alzheimer’s Market - StocksToTrade
INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints - TipRanks
INmune Bio rises as prostate cancer therapy meets trial goals - TradingView
INmune Bio’s Future: Buying, Holding, or Selling? - timothysykes.com
INmune Bio stock up as prostate cancer trial succeeds (INMB) - Seeking Alpha
Volume Profile Shows Strong Base for INmune Bio Inc.Target Return Focused Trade Insights Shared - metal.it
INmune Bio Stock Soars 25.78% on Pipeline Advancements - AInvest
INmune Bio stock soars after prostate cancer trial meets endpoints By Investing.com - Investing.com Australia
INmune Bio stock soars after prostate cancer trial meets endpoints - Investing.com
INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan
When is INmune Bio Inc. stock expected to show significant growthFree Bull & Bear Market Updates - Jammu Links News
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inmune Bio Inc 주식 (INMB) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
자본화:
|
볼륨(24시간):